Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orly Lipsitz

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Psychiatry Research|July 10, 2021
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemicJoshua D Rosenblat, Orly Lipsitz, Joshua D Di Vincenzo, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
Journal of Psychopharmacology (Oxford, England)|November 15, 2022
Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Psychiatry Research|May 25, 2021
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)Roger S McIntyre, Joshua D Rosenblat, Nelson B Rodrigues, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
CNS Spectrums|January 19, 2021
The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid DatasetLeanna M W Lui, Yena Lee, Orly Lipsitz, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 24, 2025
Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trialDanica E Johnson, Shakila Meshkat, Erica S Kaczmarek, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Psychiatry Research|July 10, 2021
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemicJoshua D Rosenblat, Orly Lipsitz, Joshua D Di Vincenzo, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
Journal of Psychopharmacology (Oxford, England)|November 15, 2022
Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Psychiatry Research|May 25, 2021
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)Roger S McIntyre, Joshua D Rosenblat, Nelson B Rodrigues, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
CNS Spectrums|January 19, 2021
The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid DatasetLeanna M W Lui, Yena Lee, Orly Lipsitz, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 24, 2025
Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trialDanica E Johnson, Shakila Meshkat, Erica S Kaczmarek, et al.
Pageof 6